This pilot early phase I trial studies how well diffusion weighed-magnetic resonance imaging (DW-MRI) works in diagnosing patients with head and neck cancer or thyroid cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. Dynamic contrast enhanced–magnetic resonance imaging (DCE-MRI) uses faster imaging and contrast material (a substance used to make specific organs, blood vessels, or tumors easier to see) that is given by vein. New MRI methods may give doctors more information about the tumor.
Additional locations may be listed on ClinicalTrials.gov for NCT03483337.
Locations matching your search criteria
United States
New York
New York
Memorial Sloan Kettering Cancer CenterStatus: Active
Contact: Amita Shukla-Dave
Phone: 212-639-3184
PRIMARY OBJECTIVES:
I. To develop and standardize a multi b-value reduced field of view (rFOV) DW-MRI acquisition method and non-mono exponential modeling DW-MRI along with DCE-MRI acquisition and modeling for oncology applications.
II. To develop and implement quantitative MRI biomarkers in patients with recurrent/metastatic (R/M) malignancies in the head and neck (HN) region for oncology applications.
III. To establish the next generation DW- and DCE- MRI biomarkers as prognostic and/or predictive indicators in investigational therapies using recurrent, metastatic or definitive head and neck cancers or differentiated and undifferentiated thyroid cancers as a proof of principle model.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I: Patients with recurrent or metastatic head and neck cancer undergo MRI and DW-MRI test-retest scan over 50-60 minutes in one session prior to standard of care treatment. Patients who will be receiving radiation therapy treatment will also be imaged weekly during their course of treatment.
GROUP II: Patients with recurrent, metastatic or definitive head and neck cancer or differentiated and undifferentiated thyroid cancer undergo MRI, DW-MRI, and DCE-MRI over 50-60 minutes once within 1 week prior to standard of care treatment initiation. Patients receiving radiation therapy may also undergo DCE-MRI during weeks 2 and 4 of treatment.
After completion of study, patients are followed up to 1 year.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorAmita Shukla-Dave
